AKBA - שווי כולל של החברה Akebia Corp

The Enterprise Value valuation for Akebia Therapeutics (AKBA), reaching 249.33, is supported by stable production line operations and equipment calibration. Akebia Therapeutics (AKBA) develops innovative Vafseo tablets, sparing renal anemia patients from painful injections. Business revenues are based on supplies to dialysis centers, where therapy costs are reimbursed by insurance companies and Medicare government programs.

Enterprise value reflects the total cost of acquiring a business, accounting for all liabilities and liquidity. The algorithm combines market capitalization and debt, subtracting cash to determine the actual capital. The trend in estimated enterprise value allows for the filtering of speculative noise from fundamental growth. For Akebia Therapeutics (AKBA), this indicator confirms the capitalization of a closed supply ecosystem for Vafseo in dialysis centers. The stability of the therapy minimizes risks, bolstering the asset value with real market advantages.